Jun Gong MD
Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CaliforniaJun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers.
Disclosures
Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.
Recent Contributions to PracticeUpdate:
- Plasma cfDNA Variant Analysis Compared With Methylated DNA Analysis in RCC
- Prevalence of Cigarette Smoking Among Patients With Different Histological Types of Kidney Cancer
- Deferred Cytoreductive Nephrectomy in Patients With Newly Diagnosed mRCC
- Construction and Validation of a Novel Prognostic Nomogram for Patients With Sarcomatoid RCC
- Activity of Vorolanib + Everolimus in Patients With Advanced Clear Cell Renal Cell Carcinoma
- PBRM1 Loss Defines a Nonimmunogenic Tumor Phenotype Associated With Checkpoint Inhibitor Resistance in RCC
- Impact of Pathologic Lymph Node–Positive RCC on Survival in Patients Without Metastasis
- Cabozantinib vs Everolimus in Patients With Advanced RCC: Outcomes by Nephrectomy Status
- Whole-Body Diffusion-Weighted MRI for Detection of Bone Metastases in mRCC Patients Treated With Angiogenesis Inhibitors
- Patient-Reported Outcomes With Atezolizumab + Bevacizumab vs Sunitinib in Treatment-Naïve Metastatic RCC